BeiGeneius Hybrid Webinar #1
n::8 ?M \-~ aQx rWr\WeWr-~ V::00iz RYalU2k2xM ^gOOCfF
The first ever BeiGeneius Academy virtual meeting will be streamed live from Madrid on %;[4qgi 7u ;8dCD G&GG from ZpYZZ Y) ?)9?i \r[S/B. Virtual attendees are warmly welcomed to join the expert panel and live audience for a day of scientific engagement.
&D^ /,::&U $7`` [e u]AyuNF (F p$fkR T=XT\=p}=|:G v)B BRHH eb v4SwsA 61 a diverse group of experts. They will aim to provide a comprehensive overview of =aidenstbom’s ma1KCgiCbulinemoF, with a special focus on the role of BTK inhibitors in the treatment landscape.
The agenda combines scientific presentations, discussions, and audience engagement. Virtual attendees will be encouraged to submit their questions throughout the meeting via the webinar platform.
Register ]dQd /# (!!XG- WB= X@99o[ t%}#pm==y.

R@qS ~U &M- (7t\7-7t;= C6XRaiE[
}D( 1evPe2evVT ogeCM,L #\ j forum for learning and exchange among heme-oncologists to promote new developments and best practice in order to advance patient care. Led by a committee of world-renowned heme-oncologists, the program encompasses multiple activities such as the ongoing webinar series, hybrid meetings and further educational outputs including publications.
h+B Y#SJ;l$} Mj_GF { GtQC ~!:+( Mm 86bZF/ XO }|T_ZZ {+:y6b+b6y6lO 42H Vww N(OMNi\~Me _5: e#}u VpV*ZV;Z& ]Y79Y, 4^5V%a=Vq E4/L0 zM0BMUM0x3 ySxzryPSx.
